There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray- administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose.Se provee una composición farmacéutica anticonvulsiva transnasal que incluye un anticonvulsivante escasamente soluble； la composición farmacéutica anticonvulsiva que comprende como ingrediente activo un anticonvulsivante escasamente soluble, que se administra como aerosol por vía transnasal, comprende éter monoetílico de dietilenglicol y un éster de ácido graso, en donde el éster de ácido graso se selecciona del grupo que consiste en caprilocaproil polioxilglicérido, palmitato de isopropilo, oleoil polioxilglicérido, monolaurato de sorbitán 20, laurato de metilo, laurato de etilo y polisorbato 20； también, la composición farmacéutica anticonvulsiva que comprende como ingrediente activo un anticonvulsivante escasamente soluble, que se admin
